Latest News

Jim Merselis takes over at Biosensia as Company Prepares for Commercialisation

Dublin, Tuesday 19 February 2013 … Biosensia Ltd., a point of care diagnostics company, today announces the appointment of James D. Merselis as Chief Executive Officer.  Jim joins as the company seeks to secure regulatory approval for RapiPlex, its Point of Care platform, and continues to progress a pipeline of commercial deals. Jim joined Biosensia in 2012 as a non...


Veryan Receives CE Mark Approval for BioMimics 3D™ Stent

16 November 2012 – Seroba Kernel investee company, Veryan Medical, the vascular disease specialist, has received CE Mark approval for the BioMimics 3D™ stent, its novel platform technology designed for treatment of the superficial femoral and proximal popliteal (femoropopliteal) arteries of the leg. The BioMimics 3D™ stent features a unique three-dimensional design that...


Biosensia appoints James D. Merselis as Non-Executive Director.

Dublin, 23 October 2012 … Biosensia ltd., a Seroba Kernel backed point of care diagnostics Company, today announces the appointment of James D. Merselis as Non-Executive Director. Jim is currently a non-executive director at Trinity Biotech (NASDAQ: TRIB) and a consultant to healthcare diagnostics companies. He was formerly President and CEO of ITC Nexus Dx, Inc, a privately...


< back to home page